Full article here
Lauxera Capital Partners, a Paris, France- and San Francisco, CA-based growth-buyout and growth equity firm focused on Healthtech companies, closed Lauxera Growth Il, at €520m. Backers included both returning and new Limited Partners.
The fund, classified as an Article 8 fund under SFDR, plans to deploy capital across 12 to 15 companies, with individual investments of €20 to €50m focused on US and global market expansion. Lauxera’s expertise extends across commercial-stage Healthtech sub-sectors, including medical devices, pharma and medtech services, digital health, healthcare data and software, and life science tools and diagnostics.
Lauxera Growth Il made two investments to date, including:
• a minority investment in German neurovascular device innovator Acandis, and
• a majority investment in Swedish advanced imaging CRO Antaros Medical.
Founded in 2020, Lauxera Capital Partners manages more than $1bn in assets and supports 13 portfolio companies as a hands-on operational and financial partner.
Since 2021, portfolio companies as a whole have created more than 400 jobs, launched dozens of new products in the US and globally, and completed over a dozen boit-on transactions. ln 2025, the firm exited OrganOx, which was acquired in October 2025 by the Japanese group Terumo for approximately $1.5 billion.
